BriaCell Quadruples PFS in Metastatic Breast Cancer

BriaCell Therapeutics Corp., a clinical-stage biotechnology company, reports a significant improvement in progression-free survival (PFS) for a top responder in their Phase 2 study of the Bria-IMT™ regimen combined with an immune checkpoint inhibitor for treating metastatic breast cancer. This patient, who continues to receive BriaCell’s treatment, has seen her PFS extended to 9.1 months, quadruple compared to patients in similar studies.

Dr. William V. Williams, BriaCell’s President and CEO, expressed his satisfaction with the unprecedented survival benefit observed in this difficult-to-treat patient. He emphasized that this data signifies a major advancement in their mission to use their knowledge and successes to revolutionize cancer care. Dr. Williams also noted their intention to replicate this promising data in their ongoing Phase 3 study, aiming to provide relief to cancer patients with unmet medical needs.

Metastatic breast cancer remains a significant challenge despite recent advancements in cancer therapies, as highlighted by BriaCell’s Chief Medical Officer, Dr. Giuseppe Del Priore. Current treatments are often limited by poor survival rates and severe side effects. However, the Bria-IMT™ regimen has shown a notably longer-than-expected survival benefit in addition to its favorable safety and tolerability profile in this patient, suggesting its potential as a viable therapeutic option for these cancer patients.

The patient in question had a substantial lesion behind her right eye and another in the right temporal lobe of her brain. Remarkably, the temporal lobe lesion is no longer detectable, and the orbital lesion has significantly shrunk. Additionally, her tumor markers, which correlate with the tumor's presence in the body, have drastically decreased from pre-treatment levels.

In comparison to historical clinical data, the PFS for BriaCell’s top responder patient stands out significantly. For instance, in studies conducted by Bardia et al., Tripathy et al., and O'Shaughnessy et al., PFS for metastatic breast cancer patients who had failed multiple prior treatments ranged from 1.6 to 2.3 months. The top responder in BriaCell’s study, however, has experienced a PFS of 9.1 months and counting.

BriaCell Therapeutics Corp. continues to advance its development of novel immunotherapies aimed at transforming the landscape of cancer treatment. The promising results from the Phase 2 study of the Bria-IMT™ regimen, particularly in extending PFS in a heavily pre-treated metastatic breast cancer patient, underscore the potential of this therapeutic approach to provide significant benefits where current treatments fall short.

BriaCell remains optimistic about replicating these positive outcomes in their ongoing Phase 3 studies, with the ultimate goal of bringing effective relief to cancer patients with previously limited options.